Mangoceuticals, Inc. has announced a series of significant corporate events, including the issuance of Series B Convertible Preferred Stock and associated Warrants, an Equity Line of Credit (ELOC) agreement, and the acquisition of patents through the issuance of Series C Convertible Preferred Stock. The company has entered into a Securities Purchase Agreement (SPA) with an institutional accredited investor to sell Series B Preferred Stock and Warrants, potentially resulting in the issuance of more than 20% of the company's outstanding common stock. Additionally, the ELOC agreement with the same investor could see the sale of common stock up to $25 million, subject to stockholder approval. Mangoceuticals also acquired patents related to infection prevention from Intramont Technologies, Inc. in exchange for Series C...Show More

Mangoceuticals, Inc. has announced a series of significant corporate events, including the issuance of Series B Convertible Preferred Stock and associated Warrants, an Equity Line of Credit (ELOC) agreement, and the acquisition of patents through the issuance of Series C Convertible Preferred Stock. The company has entered into a Securities Purchase Agreement (SPA) with an institutional accredited investor to sell Series B Preferred Stock and Warrants, potentially resulting in the issuance of more than 20% of the company's outstanding common stock. Additionally, the ELOC agreement with the same investor could see the sale of common stock up to $25 million, subject to stockholder approval. Mangoceuticals also acquired patents related to infection prevention from Intramont Technologies, Inc. in exchange for Series C Preferred Stock valued at $19.6 million and cash payments totaling $400,000. These transactions are subject to stockholder approval in compliance with Nasdaq Listing Rules 5635(a) and (d). The company has also engaged Turner, Stone & Company, L.L.P. as its independent registered public accounting firm for the fiscal year ending December 31, 2024, and is seeking stockholder ratification of this appointment.